Search results for "double-blind method"

showing 10 items of 631 documents

Working-Age Cataract Patients: Visual Results, Reading Performance, and Quality of Life with Three Diffractive Multifocal Intraocular Lenses

2013

Purpose To compare the visual outcomes, reading performance, and quality of life (QoL) of working-age cataractous patients bilaterally implanted with 3 different diffractive multifocal intraocular lenses (MIOLs). Design Two-center, randomized, prospective, double-masked study. Participants Sixty-three consecutive patients (126 eyes) seen at Ophthalmology Section, Palermo and Florence University, Italy, randomized to receive the ReSTOR SN6AD3 (Alcon Laboratories, Inc, Irvine, CA) (20 patients, group A), ReSTOR SN6AD1 (Alcon Laboratories, Inc) (21 patients, group B), or TECNIS ZMA00 (Abbott Medical Optics, Santa Ana, CA) (22 patients, group C) MIOL. Intervention Phacoemulsification. Main Outc…

MaleRefractive errorVisual acuitygenetic structuresMesopic visionmedicine.medical_treatmentMesopic VisionVisual AcuitySettore MED/42 - Igiene Generale E ApplicataLens Implantation IntraocularSickness Impact ProfileSurveys and QuestionnairesMedicineContrast (vision)Prospective StudiesProspective cohort studyOPTICAL-QUALITYmedia_commonLenses IntraocularVision BinocularOUTCOMESMiddle AgedRESTORFemalemedicine.symptomA+3.00 DPhotopic visionDIOPTER ADDITIONmedicine.medical_specialtyINSTITUTE-REFRACTIVE ERRORmedia_common.quotation_subjectMODELSProsthesis DesignCataractDouble-Blind MethodOphthalmologyCONTRAST SENSITIVITYHumansBILATERAL IMPLANTATIONPhacoemulsificationColor Visionbusiness.industrySettore MED/30 - Malattie Apparato VisivoPhacoemulsificationMultifocal intraocular lensmedicine.diseaseeye diseasesOphthalmologyVISIONINSTITUTE-REFRACTIVE ERROR; CONTRAST SENSITIVITY; BILATERAL IMPLANTATION; DIOPTER ADDITION; OPTICAL-QUALITY; A+3.00 D; VISION; RESTOR; OUTCOMES; MODELSReadingQuality of LifeOptometryMultifocal IOL diffractive Quality of lifebusinessFollow-Up Studies
researchProduct

Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): ra…

2004

Summary Background Clopidogrel was superior to aspirin in patients with previous manifestations of atherothrombotic disease in the CAPRIE study and its benefit was amplified in some high-risk subgroups of patients. We aimed to assess whether addition of aspirin to clopidogrel could have a greater benefit than clopidogrel alone in prevention of vascular events with potentially higher bleeding risk. Methods We did a randomised, double-blind, placebo-controlled trial to compare aspirin (75 mg/day) with placebo in 7599 high-risk patients with recent ischaemic stroke or transient ischaemic attack and at least one additional vascular risk factor who were already receiving clopidogrel 75 mg/day. D…

MaleRelative risk reductionTiclopidineHemorrhage030204 cardiovascular system & hematologyKlinikai orvostudományok03 medical and health sciences0302 clinical medicineDouble-Blind MethodRecurrenceRisk FactorsmedicineClinical endpointHumanscardiovascular diseasesMyocardial infarctionRisk factorStrokeAgedAspirinAspirinbusiness.industryAbsolute risk reductionGeneral MedicineOrvostudományokmedicine.diseaseClopidogrelClopidogrel3. Good healthStrokeIschemic Attack TransientAnesthesiaDrug Therapy CombinationFemalebusinessIntracranial HemorrhagesPlatelet Aggregation Inhibitors030217 neurology & neurosurgerymedicine.drug
researchProduct

A post-trial survey to assess the impact of dissemination of results and unmasking on participants in a 13-year randomised controlled trial on age-re…

2011

Abstract Background The Italian-American Clinical Trial of Nutritional Supplements and Age-Related Cataract was designed to assess the impact of a multivitamin-mineral supplement on age-related cataract. Trial results showed evidence of a beneficial effect of the supplement on all types of cataract combined, opposite effects on two of the three types of cataract (beneficial for nuclear opacities and harmful for posterior sub-capsular opacities) and no statistically significant effect on cortical opacities. No treatment recommendations were made. A post-trial survey was conducted on 817 surviving elderly participants to assess their satisfaction, their understanding of treatment assignment t…

MaleResearch designAgingHealth Knowledge Attitudes Practicemedicine.medical_specialtyTime FactorsMEDLINEMedicine (miscellaneous)PlaceboCataractlaw.inventionPatient satisfactionDouble-Blind MethodRandomized controlled triallawSurveys and QuestionnairesHumansMedicinePharmacology (medical)AgedAged 80 and overMineralslcsh:R5-920Chi-Square DistributionInformation Disseminationbusiness.industryResearchAge FactorsVitaminsMiddle AgedCorrespondence as TopicSurgeryClinical trialDrug CombinationsTreatment OutcomePatient SatisfactionResearch DesignDietary SupplementsPhysical therapyFemaleComprehensionbusinessAge-related cataractlcsh:Medicine (General)Chi-squared distributionTrials
researchProduct

Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI…

2001

Summary Background Despite the use of aspirin, there is still a risk of ischaemic events after percutaneous coronary intervention (PCI). We aimed to find out whether, in addition to aspirin, pretreatment with clopidogrel followed by long-term therapy after PCI is superior to a strategy of no pretreatment and short-term therapy for only 4 weeks after PCI. Methods 2658 patients with non-ST-elevation acute coronary syndrome undergoing PCI in the CURE study had been randomly assigned double-blind treatment with clopidogrel (n=1313) or placebo (n=1345). Patients were pretreated with aspirin and study drug for a median of 6 days before PCI during the initial hospital admission, and for a median o…

MaleRiskAcute coronary syndromePrasugrelTiclopidinemedicine.medical_treatmentMyocardial InfarctionCoronary DiseaseDouble-Blind MethodPreoperative CaremedicineMyocardial RevascularizationHumansMyocardial infarctionProspective Studiescardiovascular diseasesAngioplasty Balloon CoronaryAgedProportional Hazards ModelsManagement of acute coronary syndromeAspirinbusiness.industryPercutaneous coronary interventionGeneral MedicineMiddle AgedClopidogrelmedicine.diseaseSurvival AnalysisClopidogrelLogistic ModelsTreatment OutcomeAnesthesiaConventional PCIFemalebusinessElinogrelPlatelet Aggregation Inhibitorsmedicine.drug
researchProduct

Effect of hydrolyzed infant formula vs conventional formula on risk of type 1 diabetes the TRIGR randomized clinical trial

2018

IMPORTANCE Early exposure to complex dietary proteins may increase the risk of type 1 diabetes in children with genetic disease susceptibility. There are no intact proteins in extensively hydrolyzed formulas. OBJECTIVE To test the hypothesis that weaning to an extensively hydrolyzed formula decreases the cumulative incidence of type 1 diabetes in young children. DESIGN, SETTING, AND PARTICIPANTS An international double-blind randomized clinical trial of 2159 infants with human leukocyte antigen-conferred disease susceptibility and a first-degree relative with type 1 diabetes recruited from May 2002 to January 2007 in 78 study centers in 15 countries; 1081 were randomized to be weaned to the…

MaleRiskmedicine.medical_specialtyCaseinBreastfeeding030209 endocrinology & metabolism610 Medicine & health2700 General MedicineEndocrinology and DiabetesDisease-Free Survivallaw.inventionFollow-Up StudieNutrition Policy03 medical and health sciences0302 clinical medicineRandomized controlled trialDouble-Blind MethodSDG 3 - Good Health and Well-beinglawInternal medicineDiabetes mellitusmedicineHumansCumulative incidence030212 general & internal medicineChildInfant Nutritional Physiological PhenomenaOriginal Investigation2. Zero hungerType 1 diabetesbusiness.industryHazard ratioAbsolute risk reductionInfant NewbornCaseinsGeneral Medicineta3121medicine.diseaseInfant Formula3. Good healthDiabetes Mellitus Type 1Infant formula10036 Medical ClinicEndokrinologi och diabetesFemalebusinessHumanFollow-Up Studies
researchProduct

Mongersen, an oral SMAD7 antisense oligonucleotide, and crohn's disease

2015

Crohn's disease-related inflammation is characterized by reduced activity of the immunosuppressive cytokine transforming growth factor β1 (TGF-β1) due to high levels of SMAD7, an inhibitor of TGF-β1 signaling. Preclinical studies and a phase 1 study have shown that an oral SMAD7 antisense oligonucleotide, mongersen, targets ileal and colonic SMAD7.In a double-blind, placebo-controlled, phase 2 trial, we evaluated the efficacy of mongersen for the treatment of persons with active Crohn's disease. Patients were randomly assigned to receive 10, 40, or 160 mg of mongersen or placebo per day for 2 weeks. The primary outcomes were clinical remission at day 15, defined as a Crohn's Disease Activit…

MaleSMAD7 antisense oligonucleotidemedicine.medical_treatmentOligonucleotidesPharmacologyPLACEBO-CONTROLLED TRIALTHERAPYGastroenterologylaw.inventionACTIVATIONImmunosuppressive AgentGlucocorticoidRandomized controlled trialCrohn DiseaselawOligonucleotideMedicineYoung adultCrohn's diseaseSettore MED/12 - GastroenterologiabiologyINDUCTIONMedicine (all)Remission InductionGeneral MedicineMiddle AgedCrohn's diseaseCytokineC-Reactive ProteinCombinationDrug Therapy CombinationFemaleDrugImmunosuppressive AgentsCOLITISHumanAdultmedicine.medical_specialtyAdolescentINFLAMMATORY-BOWEL-DISEASE PLACEBO-CONTROLLED TRIAL NECROSIS-FACTOR-ALPHA TGF-BETA-1-MEDIATED SUPPRESSION COLITIS INDUCTION ACTIVATION EFFICACY THERAPY MICEPlaceboSmad7 ProteinDose-Response RelationshipYoung AdultPharmacotherapyDouble-Blind MethodDrug TherapyInternal medicineHumansAntisenseGlucocorticoidsAgedDose-Response Relationship Drugbusiness.industryC-reactive proteinNECROSIS-FACTOR-ALPHAOligonucleotides AntisenseTGF-BETA-1-MEDIATED SUPPRESSIONEFFICACYmedicine.diseaseClinical trialMICEbiology.proteinbusinessAdolescent; Adult; Aged; C-Reactive Protein; Crohn Disease; Dose-Response Relationship Drug; Double-Blind Method; Drug Therapy Combination; Female; Glucocorticoids; Humans; Immunosuppressive Agents; Male; Middle Aged; Oligonucleotides; Oligonucleotides Antisense; Remission Induction; Smad7 Protein; Young Adult; Medicine (all)INFLAMMATORY-BOWEL-DISEASE
researchProduct

Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients

2017

Item does not contain fulltext BACKGROUND: Bococizumab is a humanized monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9) and reduces levels of low-density lipoprotein (LDL) cholesterol. We sought to evaluate the efficacy of bococizumab in patients at high cardiovascular risk. METHODS: In two parallel, multinational trials with different entry criteria for LDL cholesterol levels, we randomly assigned the 27,438 patients in the combined trials to receive bococizumab (at a dose of 150 mg) subcutaneously every 2 weeks or placebo. The primary end point was nonfatal myocardial infarction, nonfatal stroke, hospitalization for unstable angina requiring urgent re…

MaleSTATIN THERAPYAnticholesteremic Agents/adverse effectsAntibodieVascular damage Radboud Institute for Health Sciences [Radboudumc 16]Injections Subcutaneous/adverse effects030204 cardiovascular system & hematologyBococizumablaw.inventionPCSK90302 clinical medicineRandomized controlled triallawRisk FactorsGENETIC-VARIANTSCardiovascular DiseaseMonoclonalAnticholesteremic Agent030212 general & internal medicineMyocardial infarctionTreatment FailureHumanizedProprotein Convertase 9/antagonists & inhibitorsMedicine(all)Antibodies; Antibodies Monoclonal Humanized; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol LDL; Double-Blind Method; Female; Follow-Up Studies; Humans; Hypercholesterolemia; Injections Subcutaneous; Lipids; Male; Middle Aged; Proprotein Convertase 9; Risk Factors; Treatment Failure; Medicine (all)Anticholesteremic AgentsMedicine (all)PCSK9 InhibitorsAntibodies; antibodies monoclonal humanized; anticholesteremic agents; cardiovascular diseases; cholesterol LDL; double-blind method; female; follow-up studies; humans; hypercholesterolemia; injections subcutaneous; lipids; male; middle aged; proprotein convertase 9; risk factors; treatment failure; medicine (all)Vascular damage Radboud Institute for Molecular Life Sciences [Radboudumc 16]General MedicineLipidMiddle AgedLipids3. Good healthLDL/bloodMulticenter StudyCholesterolTRIALSCholesterol LDL/bloodCardiovascular DiseasesAntibodies Monoclonal Humanized/adverse effectsanticholesteremic agentsRandomized Controlled Trialsubcutaneouslipids (amino acids peptides and proteins)FemaleProprotein Convertase 9Cardiovascular Diseases/prevention & controlREDUCING LIPIDSHumanmedicine.medical_specialtyanimal structuresInjections SubcutaneousHypercholesterolemiaHypercholesterolemia/drug therapyPlaceboAntibodies Monoclonal HumanizedInjections SubcutaneouAntibodiesLDLInjectionsFollow-Up StudielipidsEVENTS03 medical and health sciencesantibodies monoclonal humanizedDouble-Blind MethodInternal medicinemedicineJournal ArticleHumansComparative StudyMETAANALYSISAlirocumabbusiness.industryUnstable anginaLipids/bloodPCSK9Risk FactorfungiAntibodies/bloodCholesterol LDLta3121medicine.diseaseSurgerycardiovascular diseasesEvolocumabREDUCTIONHumanized/adverse effectsSubcutaneous/adverse effectsbusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyFollow-Up Studies
researchProduct

Effectiveness of malic acid 1% in patients with xerostomia induced by antihypertensive drugs

2012

Objectives: Assessing the clinical effectiveness of a topical sialogogue on spray (malic acid, 1%) in the treatment of xerostomia induced by antihypertensive drugs. Study Design: This research has been carried out through a randomized double-blind clinical trial. 45 patients suffering from hypertensive drugs-induced xerostomia were divided into 2 groups: the first group (25 patients) received a topical sialogogue on spray (malic acid, 1%) whereas the second group (20 patients) received a placebo. Both of them were administered on demand for 2 weeks. Dry Mouth Questionnaire (DMQ) was used in order to evaluate xerostomia levels before and after product/placebo application. Unstimulated and st…

MaleSalivamedicine.medical_specialtyMalatesOdontologíaPlaceboDontostomatology for the Disabled or Special PatientsGastroenterologyXerostomialaw.inventionchemistry.chemical_compoundRandomized controlled trialDouble-Blind MethodlawInternal medicineSurveys and QuestionnairesmedicineHumansIn patientSialogogueGeneral DentistryAntihypertensive Agentsbusiness.industryMiddle AgedDry mouth:CIENCIAS MÉDICAS [UNESCO]Ciencias de la saludClinical trialEndocrinologyOtorhinolaryngologychemistryUNESCO::CIENCIAS MÉDICASSurgeryResearch-ArticleFemaleMalic acidmedicine.symptombusiness
researchProduct

Immune response to 13-valent pneumococcal conjugate vaccine with a reduced dosing schedule

2013

Background: The 7-valent pneumococcal conjugate vaccine (PCV7) has demonstrated effectiveness against pneumococcal illnesses when administered as 3 infant doses plus a toddler dose (3+1 schedule) or as an abbreviated schedule of 2 infant doses plus a toddler dose (2+1 schedule). The 13-valent pneumococcal conjugate vaccine (PCV13) is approved and World Health Organization-prequalified for administration in a 2+1 schedule when used as part of routine immunization programs. Objective: To summarize immunologic responses elicited by PCV13 administered in a 2+1 schedule and following 2 doses in a 3+1 schedule. Methods: Studies were double-blind, randomized, active-controlled, multicenter studies…

MaleSerotypePCV132+12+1; Immune response; PCV13; Pediatric; Pneumococcal conjugate vaccinePneumococcal InfectionsPneumococcal conjugate vaccinePneumococcal VaccinesDouble-Blind MethodHumansMedicineDosingToddlerImmune responseMexicoPediatricGeneral VeterinaryGeneral Immunology and Microbiologybiologybusiness.industryImmunogenicityPneumococcal conjugate vaccineVaccinationPublic Health Environmental and Occupational HealthInfantAntibodies BacterialUnited KingdomClinical trialInfectious DiseasesItalySpainImmunoglobulin GConcomitantImmunologybiology.proteinMolecular MedicineFemaleAntibodybusinessmedicine.drug
researchProduct

The long-term effects of probiotics in the therapy of ulcerative colitis: a clinical study

2016

Aim: Intestinal dysbiosis seems to be the leading cause of inflammatory bowel diseases, and probiotics seems to represent the proper support against their occurrence. Actually, probiotic blends and anti-inflammatory drugs represent a weapon against inflammatory bowel diseases. The present study evaluates the long-term (2 years) effects of combination therapy (mesalazine plus a probiotic blend of Lactobacillus salivarius, Lactobacillus acidophilus and Bifidobacterium bifidus strain BGN4) on ulcerative colitis activity. Method: Sixty patients with moderate-to-severe ulcerative colitis were enrolled: 30 of them were treated with a single daily oral administration of mesalazine 1200 mg; 30 pati…

MaleSettore MED/07 - Microbiologia E Microbiologia Clinicaved/biology.organism_classification_rank.specieslcsh:MedicineGastroenterologyInflammatory bowel diseaselaw.inventionProbioticchemistry.chemical_compound0302 clinical medicineLactobacillus acidophiluslawMesalamineBifidobacteriumSettore MED/12 - GastroenterologiabiologyLactobacillus salivariusMicrobiotaMedicine (all)Anti-Inflammatory Agents Non-Steroidalfood and beveragesMiddle AgedUlcerative colitisLactobacillus acidophilusTreatment Outcome030220 oncology & carcinogenesis030211 gastroenterology & hepatologyDrug Therapy CombinationFemaleBifidobacteria; Inflammatory bowel diseases; Lactobacilli; Microbiota; Ulcerative colitis; Medicine (all); Biochemistry Genetics and Molecular Biology (all)Adultmedicine.medical_specialtyCombination therapyinflammatory bowel diseasesGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciencesMesalazineDouble-Blind MethodBifidobacteriaInternal medicinemedicineHumansulcerative colitisAgedAnalysis of VarianceBifidobacterium bifidumUlcerative colitiBiochemistry Genetics and Molecular Biology (all)ved/biologybusiness.industryProbioticslcsh:Rbiology.organism_classificationmedicine.diseaseSettore MED/18 - Chirurgia GeneralechemistryLactobacilliLigilactobacillus salivariusColitis UlcerativeBifidobacterium bifidumbusiness
researchProduct